---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-055242"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:22:21.035844+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# uniQure Q1 net loss $53.5M ($0.85/share); AMT-130 UK MAA on track for Q3

## Summary
- Net loss of $53.5M vs $43.6M YoY; revenue $3.6M up from $1.6M on license revenue.
- Cash $586.6M; runway into H2 2029; R&D down 19% to $29.2M, SG&A up 84% to $20.1M.
- FDA Type B meeting scheduled Q2 2026 for AMT-130; UK MAA submission expected Q3 2026.
- AMT-260 cohort 2 enrollment on track mid-2026; data from first cohort at June 2026 conference.
- AMT-191 dosing paused at mid/high dose due to liver enzyme DLTs; all 11 patients off ERT.

## SEC filing metadata
- accession: 0001104659-26-055242
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/qure-20260505x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-055242
- JSON: https://secwatch.observer/filing/0001104659-26-055242.json
- Plain text: https://secwatch.observer/filing/0001104659-26-055242.txt

## Source-grounded claims
- claim_id: ff12cb5a3472abb9886e5bad94d25b96da6c5cbb
  claim: uniQure N.V. reported financial results for first quarter of 2026.
  evidence_excerpt: uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm
- claim_id: ff12cb5a3472abb9886e5bad94d25b96da6c5cbb
  claim: uniQure N.V. reported financial results for first quarter of 2026.
  evidence_excerpt: Strong balance sheet with $586.6 million in cash, cash equivalents and current investment securities as of March 31, 2026 and runway into the second half of 2029
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.